[1]戴 涛,卢一思.H型高血压患者SLC34A1基因rs6420094位点多态性与肾损伤的相关性研究[J].现代检验医学杂志,2025,40(03):80-83,101.[doi:10.3969/j.issn.1671-7414.2025.03.015]
　DAI Tao,LU Yisi.Correlation between Polymorphisms at the SLC34A1 Gene rs6420094 and Renal Injury in Patients with H-type Hypertension[J].Journal of Modern Laboratory Medicine,2025,40(03):80-83,101.[doi:10.3969/j.issn.1671-7414.2025.03.015]
点击复制

H型高血压患者SLC34A1基因rs6420094位点多态性与肾损伤的相关性研究()

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年03期
页码:
80-83,101
栏目:
论著
出版日期:
2025-05-15

文章信息/Info

Title:
Correlation between Polymorphisms at the SLC34A1 Gene rs6420094 and Renal Injury in Patients with H-type Hypertension
文章编号:
1671-7414（2025）03-080-05
作者:
戴 涛，卢一思
（黑龙江省大庆市龙南医院乘风院区检验科，黑龙江大庆 163411）
Author(s):
DAI Tao，LU Yisi
（Department of Clinical Laboratory，Chengfeng Campus of Daqing Longnan Hospital， Heilongjiang Province，Heilongjiang Daqing 163411，China）
关键词:
H型高血压; 溶质载体家庭34成员1; 基因多态性; 肾损伤
分类号:
R544.1；Q786
DOI:
10.3969/j.issn.1671-7414.2025.03.015
文献标志码:
A
摘要:
目的探究H型高血压患者溶质载体家族34成员1（SLC34A1）基因rs6420094位点多态性与肾损伤的相关性。方法选取大庆市龙南医院乘风院区于2022年12月～2023年12月收治的128例H型高血压患者作为研究组，并根据是否发生肾损伤进一步将H型高血压患者分为损伤组（n=50）和非损伤组（n=78）。另选取同期正常健康体检者100例作为对照组。收集患者临床资料；聚合酶链反应(PCR)检测SLC34A1基因rs6420094位点基因型，比较各组基因型及等位基因位点分布频率；二元Logistic回归分析H型高血压患者发生肾损伤的影响因素；实时荧光定量PCR（qRT-PCR）检测SLC34A1表达水平；Pearson法分析SLC34A1表达水平与H型高血压肾损伤患者临床指标的相关性。结果与非损伤组相比，肾损伤组Hcy(15.57±3.62μmol/Lvs13.31±2.34μmol/L)，SCr(116.03±19.94μmol/Lvs98.52±17.65μmol/L)，尿β2-MG(0.86±0.25mg/Lvs0.59±0.21mg/L)，Cys-C(2.23±0.67mg/Lvs1.03±0.28mg/L)均升高，eGFR（86.63±9.34ml/min/1.73m2vs101.36±12.65ml/min/1.73m2）降低，差异具有统计学意义(t=4.293～14.043，均P<0.05）；对照组和研究组基因分布频率符合Hardy-Weinberg遗传平衡(χ2=0.082，0.076，均P>0.05)；SLC34A1基因rs6420094位点的等位基因和基因型频率在对照组、损伤组和非损伤组中差异具有统计学意义（χ2=6.421，13.050，均P<0.05）。与对照组相比，损伤组等位基因G以及显性模型AG+GG明显降低(χ2=5.699，10.125)；与损伤组相比，非损伤组等位基因G、显性模型AG+GG明显升高（χ2=5.079，8.412），差异具有统计学意义（均P<0.05）。二元Logistic回归分析显示，携带等位基因G或显性模型（AAvsAG+GG）是H型高血压患者发生肾损伤风险的保护因素（P<0.05）；qRT-PCR结果显示，对照组SLC34A1mRNA（1.68±0.33）表达水平明显高于研究组(1.38±0.33)，肾非损伤组明显高于损伤组（1.43±0.29vs1.29±0.21）,差异具有统计学意义（t=8.349，2.952，均P<0.05）。Peason相关性分析显示，SLC34A1表达水平与Hcy，SCr，尿β2-MG，Cys-C呈负相关(r=-0.694～-0.621，均P<0.05)，与eGFR呈正相关(r=0.692，P<0.05)。结论携带SLC34A1基因rs6420094位点等位基因G或显性模型（AG+GG）的H型高血压患者发生肾损伤的风险降低。H型高血压肾损伤患者的SLC34A1表达水平降低。
Abstract:
Objective To investigate the correlation between polymorphisms at the rs6420094 locus of the soute carrier family 34 member1(SLC34A1) gene and renal injury in patients with H-type hypertension. Methods 128 patients with H-type hypertension admitted to Daqing Longnan Hospital of Heilongjiang Province from December 2022 to December 2023 were selected as the study group, and the patients with H-type hypertension were further categorized into the injury group (n=50) and the non-injury group (n=78) according to whether or not the renal injury occurred. Another 100 cases of normal healthy medical checkups in the same period were selected as the control group. Collected clinical data of patients，the genotype of rs6420094 locus of the SLC34A1 gene was detected by polymerase chain reaction (PCR), and the distribution frequency of genotype and allele locus were compared among the groups. Binary Logistic regression analysis of factors influencing renal injury in H-type hypertension patients. Real-time fluorescence quantitative PCR (qRT PCR) was used to detect the expression level of SLC34A1. The Pearson method analyzed the correlation between SLC34A1 expression level and clinical indicators in H-type hypertensive kidney injury patients. Results Compared with the non-injured group, Hcy (15.57±3.62 μmol/L vs 13.31±2.34 μmol/L ), SCr (116.03±19.94 μmol/L vs 98.52±17.65 μmol/L), urinary β2-MG (0.86±0.25 mg/L vs 0.59±0.21 mg/L), Cys-C (2.23±0.67 mg/L vs 1.03±0.28 mg/L ) were elevated, and eGFR (86.63±9.34 ml/min/1.73m2 vs 101.36±12.65 ml/min/1.73m2) was decreased, with statistically significant differences (t=4.293 ～ 14.043，all P<0.05). The genotype distributions in the control group and study group conforms to Hardy-Weinberg genetic equilibrium (χ2=0.082, 0.076, all P>0.05). The frequencies of alleles and genotypes of the rs6420094 locus of the SLC34A1 gene in the control, injury and non-injury groups were significantly different (χ2=6.421，13.050， all P<0.05). Allele G as well as dominant model AG+GG were significantly lower in the injury group compared to the control group (χ2=5.699，10.125，all P<0.05). Compared with the injury group, allele G and dominant model AG+GG were significantly higher in the non-injury group (χ2=5.079,8.412, all P<0.05). Binary Logistic regression analysis showed that carrying allele G or dominant model (AA vs AG+GG) was a protective factor against the risk of renal injury in patients with type H hypertension (P<0.05). QRT- PCR results showed that SLC34A1 mRNA expression levels were significantly higher in the control group(1.68±0.33) than in the study group (1.38±0.21), and significantly higher in the non-injury group than in the injury group (1.43±0.29 vs 1.29±0.21),and the differences were statistically significant (t=8.349，2.952，all P<0.05). Pearson correlation analysis shows that, the relationship between SLC34A1 expression levels were negatively correlated with Hcy，SCr，urinary β2-MG，Cys-C(r=-0.694 ～ -0.621，all P<0.05),and positively correlated with eGFR(r=0.692， P<0.05).Conclusion Carrying the allele G or dominant model (AG+GG) of the SLC34A1 gene rs6420094 locus in patients with H-type hypertension reduces the risk of renal injury. The expression level of SLC34A1 in patients with H-type hypertensive renal injury is decreased.

参考文献/References:

[1] FAN Fangfang, DAVID SPENCE J, HUO Yong. Beyond hypertension: hypertension with hyperhomocysteinemia [J]. Science Bulletin, 2023, 68(18): 1975-1977.
[2] DENG Yawen, LI Zhitong, AN Xiangbo, et al. Hyperhomocysteinemia promotes cardiac hypertrophy in hypertension [J]. Oxidative Medicine and Cellular Longevity, 2022, 2022: 1486157.
[3] LI Gang, ZHANG Yanyan, ZHU Zhongwei, et al. Evaluation of platelet distribution width in hypertension with hyperhomocysteinemia[J].Clinical and Experimental Hypertension, 2020, 42(1): 61-66.
[4] WAGNER C A, RUBIO-ALIAGA I, HERNANDO N. Renal phosphate handling and inherited disorders of phosphate reabsorption: an update[J].Pediatric Nephrology, 2019, 34(4): 549-559.
[5] QIU Jiechuan, WANG Zicheng, XU Yingkun, et al. Low expression of SLC34A1 is associated with poor prognosis in clear cell renal cell carcinoma[J]. BMC Urology, 2023, 23(1): 45.
[6] GORDON R J, LI Dong, DOYLE D, et al. Digenic heterozygous mutations in SLC34A3 and SLC34A1 cause dominant hypophosphatemic rickets with hypercalciuria[J]. Journal of Clinical Endocrinology &Metabolism, 2020, 105(7): 2392-2400.
[7] ZHANG Junying, CHE Tiantian, WANG Liting, et al. Proteomics coupled transcriptomics reveals SLC34A1 and SLC34A3 downregulation as potential features of nephrotoxin-induced acute kidney injury [J]. Journal of Proteomics, 2024, 302:105203.
[8] LIU Yanxiu, CHEN Yan, YANG Qiwei, et al. Single nucleotide polymorphisms in the GFR-related gene and the SNP-SNP interactions on the risk of diabetic kidney disease in Chinese Han population [J]. Acta Diabetologica, 2023, 60(1): 115-125.
[9] 汪隆海,张求霞,黄飞,等. 尿液10项生化指标联合检测及优化对高血压肾病的诊断价值研究[J]. 现代检验医学杂志, 2020, 35(4):82-86，112. WANG Longhai，ZHANG Qiuxia，HUANG Fei，et al. Study on the combined detection and optimization of urine 10 biochemical indexes in the diagnosis value of hypertensive nephropathy [J]. Journal of Modern Laboratory Medicine, 2020, 35(4):82-86，112.
[10] 孙恕,易松. 2023年《中国高血压防治指南》更新临床实践[J]. 心电与循环, 2023, 42(3):203-206,212. SUN Shu, YI Song. Clinical practice of 2023 hypertension guidelines update [J]. Journal of Electrocardiology and Circulation, 2023, 42(3):203-206,212.
[11] 牛媛瑕，王宏伟．血清Visfatin联合尿CTGF对H型高血压患者肾损伤的预测价值[J]．国际检验医学杂志，2024，45（7）：780-784． NIU Yuanxia, WANG Hongwei. Predictive value of serum Visfatin combined with urinary CTGF for renal injury in patients with H-type hypertension [J]. International Journal of Laboratory Medicine, 2024, 45(7): 780-784.
[12] CHAN G C, TEO B W, TAY J C, et al. Hypertension in a multi-ethnic Asian population of Singapore[J]. Journal of Clinical Hypertension (Greenwich, Conn.), 2021, 23(3): 522-528.
[13] 徐玉洁,高娟,王子文,等.H型高血压急性缺血性脑卒中患者亚甲基四氢叶酸还原酶C677T基因多态性及其与肾功能的相关性[J].山东医药,2024,64(6):24-28. XU Yujie, GAO Juan, WANG Ziwen, et al. MTHFR C677T gene polymorphism in patients with H-type hypertension combined with acute ischaemic stroke and its correlation with renal function [J]. Shandong Medical Journal, 2024, 64(6): 24-28.
[14] KRIZ W, WIECH T, GR?NE H J. Mesangial injury and capillary ballooning precede podocyte damage in nephrosclerosis[J]. the American Journal of Pathology, 2020, 192(12): 1670-1682.
[15] HE Xu, YANG Lingling, WANG Meiqiu, et al. Targeting ferroptosis attenuates podocytes injury and delays tubulointerstitial fibrosis in focal segmental glomerulosclerosis [J]. Biochemical and Biophysical Research Communications, 2023, 678: 11-16.
[16] LEDERER E, WAGNER CA. Clinical aspects of the phosphate transporters NaPi-IIa and NaPi-IIb: mutations and disease associations [J]. Pflügers Archiv- European Journal of Physiology, 2019, 471(1): 137-148.
[17] DUAN Aiping, WANG Hong, ZHU Yan, et al. Chromatin architecture reveals cell type-specific target genes for kidney disease risk variants[J]. BMC Biology, 2021, 19(1): 38.
[18] KANG Weiting, ZHANG Meng, WANG Qiang, et al. Corrigendum to “the SLC family are candidate diagnostic and prognostic biomarkers in clear cell renal cell carcinoma”[J]. Biomed Research International, 2020, 2020:1025178.
?

相似文献/References:

[1]程俊杰,等.高血压并发脑梗死患者不同血脂分层下病死率的分析研究[J].现代检验医学杂志,2017,32(03):97.[doi:10.3969/j.issn.1671-7414.2017.03.026]
　CHENG Jun-jie,LI Jing,et al.Significance on Cerebral Infarction’s Fatality Rate for the Retrospective Analysis of Hypertension under Serum Lipids Layer Management[J].Journal of Modern Laboratory Medicine,2017,32(03):97.[doi:10.3969/j.issn.1671-7414.2017.03.026]

备注/Memo

备注/Memo:
作者简介：戴涛(1980-)，女，回族，副主任技师，研究方向：医学检验技术，E-mail：daitao319@163.com。
更新日期/Last Update: 2025-05-15